Quest Diagnostics jumps after Q1 beat and raised 2026 revenue, EPS guidance
Quest Diagnostics shares are higher as investors react to the company’s Q1 2026 results and a raised full‑year outlook. Quest reported adjusted EPS of $2.50 on roughly $2.90B in revenue and lifted 2026 revenue and adjusted EPS guidance ranges.
1) What’s moving the stock today
Quest Diagnostics (DGX) is up about 3.4% as the market continues to price in the company’s stronger-than-expected first-quarter 2026 performance and its upward revision to full-year guidance. The catalyst is the company’s Q1 print and outlook raise, which signaled resilient demand and better operating momentum than investors were discounting.
2) The key numbers investors are reacting to
For Q1 2026, Quest reported diluted EPS of $2.24 and adjusted diluted EPS of $2.50, with net revenues about $2.90 billion. Importantly for today’s move, Quest raised its full-year 2026 outlook to revenue of $11.78 billion to $11.90 billion and adjusted EPS of $10.63 to $10.83, shifting the debate from “stable but low-growth” to “earnings durability with improving trajectory.”
3) Why it matters and what to watch next
A guidance raise tends to matter more than a one-quarter beat for diagnostics names because it indicates sustained volume, pricing/mix stability, and execution on productivity initiatives. Investors will focus next on whether Quest can keep converting revenue gains into margin expansion, how quickly newer growth areas scale, and whether additional partnerships or contract wins provide incremental upside to the raised 2026 baseline.